Evidence map›Paper›PMID 33629198›Full record

ArticleAngiogenesis2021

Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors.

Samir V Jenkins, Mohammad Alimohammadi, Alexia S Terry, Robert J Griffin, Alan J Tackett, Justin W Leung, Kieng B Vang, Stephanie D Byrum, Ruud P M Dings

Open access · greenAbstract read
In one paragraph

Article in Angiogenesis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Samir V JenkinsDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Mohammad AlimohammadiDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Alexia S TerryDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Robert J GriffinDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Alan J TackettDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Justin W LeungDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Kieng B VangCenter for Integrative Nanotechnology Sciences, University of Arkansas at Little Rock, Little Rock, AR, USA.
Stephanie D ByrumDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Ruud P M DingsDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA. rpmdings@uams.edu.ORCID http://orcid.org/0000-0001-7686-1331
University of Arkansas for Medical Sciences · USArkansas Children's Hospital · USUniversity of Arkansas at Little Rock · US

Funding

Translational Regulation in Normal Erythropoiesis and Diamond Blackfan AnemiaP20GM121293 · NIGMS · ARKANSAS CHILDREN'S HOSPITAL RES INST · PI Alan Tackett, Sean D. Taverna · 2017 to 2026
$27.6M
Study of the Cell-specific Inflammasome Responses During Defense Against Gram-negative BacteriaP20GM103625 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI AACHOUI, YOUSSEF · 2012 to 2021
$21.5M
Pilot Grant ProgramP30GM145393 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI MARK S SMELTZER · 2022 to 2026
$7.6M
Deciphering the chromatin-based DNA damage response pathwayR35GM137798 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Justin Wai Chung Leung · 2020 to 2026
$2.4M
Improvement of cellular immunotherapy during dysbiosis- ResubmissionR01CA245083 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI DINGS, RUUD P.M. · 2021 to 2025
$1.9M
Mechanistic characterization of the cell cycle-dependent DNA repair pathway- ResubmissionR01CA244261 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI Justin Wai Chung Leung · 2021 to 2026
$1.5M
J. NRSA TrainingTL1TR003109 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI SEXTON, KEVIN WAYNE · 2019 to 2023
$1.5M
The role of macroH2A-ZMYM3 in genome stability and tumorigenesisK22CA204354 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI LEUNG, JUSTIN WAI CHUNG · 2018 to 2020
$538k
NCATS NIH HHS TL1 TR003109NCI NIH HHS K22 CA204354NCI NIH HHS R01 CA244261NCI NIH HHS R01 CA245083NIGMS NIH HHS P20 GM103625NIGMS NIH HHS P20 GM121293NIGMS NIH HHS P30 GM145393NIGMS NIH HHS R35 GM137798
6 · The paper itself

Abstract

Antibiotic-induced microbial imbalance, or dysbiosis, has systemic and long-lasting effects on the host and response to cancer therapies. However, the effects on tumor endothelial cells are largely unknown. Therefore, the goal of the current study was to generate matched B16-F10 melanoma associated endothelial cell lines isolated from mice with and without antibiotic-induced dysbiosis. After validating endothelial cell markers on a genomic and proteomic level, functional angiogenesis assays (i.e., migration and tube formation) also confirmed their vasculature origin. Subsequently, we found that tumor endothelial cells derived from dysbiotic mice (TEC-Dys) were more sensitive to ionizing radiotherapy in the range of clinically-relevant hypofractionated doses, as compared to tumor endothelial cells derived from orthobiotic mice (TEC-Ortho). In order to identify tumor vasculature-associated drug targets during dysbiosis, we used tandem mass tag mass spectroscopy and focused on the statistically significant cellular membrane proteins overexpressed in TEC-Dys. By these criteria c-Met was the most differentially expressed protein, which was validated histologically by comparing tumors with or without dysbiosis. Moreover, in vitro, c-Met inhibitors Foretinib, Crizotinib and Cabozantinib were significantly more effective against TEC-Dys than TEC-Ortho. In vivo, Foretinib inhibited tumor growth to a greater extent during dysbiosis as compared to orthobiotic conditions. Thus, we surmise that tumor response in dysbiotic patients may be greatly improved by targeting dysbiosis-induced pathways, such as c-Met, distinct from the many targets suppressed due to dysbiosis.

Indexed as

DysbiosisMelanoma, ExperimentalNeovascularization, PathologicProto-Oncogene Proteins c-metAnimalsEndothelial CellsMiceProtein Kinase InhibitorsRadiotherapyProtein Kinase InhibitorsProto-Oncogene Proteins c-metc-MET inhibitorsDysbiosisEndothelial cellsForetinibHypofractionated radiationTandem mass tag mass spectroscopyTumor microenvironment

Identifiers

PMID33629198
PMCPMC8295215
OpenAlexW3133043072

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.